Sihuan Pharmaceutical (00460): Innovative drug Anjiuwei® successfully renewed its contract and was included in the 2025 National Basic Medical Insurance Drug List

Zhitong Finance App News, Sihuan Pharmaceutical (00460) issued an announcement. After a simple medical insurance renewal with the National Health Insurance Administration, the innovative drug amneprazole sodium enteric tablets (trade name: Anjiuwei®) independently developed by Xuanzhu Biotechnology Co., Ltd., a non-wholly-owned subsidiary of the Group, will continue to be included in the new “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue (2025)” (2025 National Basic Medical Insurance Drug Catalogue).

As the first and only proton pump inhibitor independently developed in China, Anjiuwei® was approved for marketing in China in June 2023 to treat duodenal ulcers, and was first included in the national basic medical insurance drug catalogue in December 2023. The successful renewal of the 2025 National Basic Medical Insurance Drug Catalogue will help stabilize market sales, continue to benefit more patients, increase the penetration rate of the product in related indications, and inject momentum into the long-term growth of Anjiuwei®.